Array/ONTY to Co-develop ARRY-380 - Analyst Blog


Shutterstock photo

Array BioPharma Inc. ( ARRY ) recently entered into an agreement with Oncothyreon Inc. ( ONTY ) to develop and commercialize ARRY-380 (ErbB2).  ARRY-380 is an orally active, reversible and selective small-molecule HER2 inhibitor.

We note that ARRY-380 has already completed phase I studies in patients with pre-treated metastatic breast cancer. The study revealed that the candidate was well tolerated and had anti-tumor activity.

ARRY-380 also demonstrated superiority with respect to overall survival in an intracranial HER2+ breast cancer xenograft model, in comparison to Tykerb (lapatinib) and neratinib. We note that Tykerb is marketed by GlaxoSmithKline ( GSK ).

Array is expected to receive an upfront fee of $10 million on the initiation of the collaboration. As per the terms of the agreement, Oncothyreon will be responsible for the development of ARRY-380 in multiple proof-of-concept studies in patients suffering from metastatic breast cancer, including patients having brain metastases. These studies will evaluate ARRY-380 in combination with other approved breast cancer drugs.

Following their completion, Array and Oncothyreon plan to jointly conduct a phase III program on ARRY-380 which will be supported by the proof-of-concept studies. Both Array and Oncothyreon will have the right to come out of further development and commercialization but will still receive royalty payments. Array expects to receive double-digit royalty payments on the candidate's approval.

While Array will be responsible for the worldwide commercialization of the candidate, Oncothyreon will enjoy co-promotion rights to the candidate in the US. The companies will be however sharing the commercialization costs and profit equally in the US. Oncothyreon is entitled to receive double-digit royalty on net sales in the ex-US market. Moreover, the companies will share any proceeds from sublicense of marketing rights equally.

Array BioPharma presently carries a Zacks Rank #3 (Hold). Meanwhile, companies like Jazz Pharmaceuticals Public Limited Company ( JAZZ ) look better positioned with a Zacks Rank #1 (Strong Buy).

ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

ONCOTHYREON INC (ONTY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: ARRY , GSK , JAZZ , ONTY

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by